Introduction/Aim. Agreement or disagreement of inflammatory parameters becomes important for making diagnosis when disparate values are encountered in a patient with suspected sepsis. The aim of our study was to test the agreement between the four commonly used tests for diagnosing systemic infection: white blood cell count (WBC), serum levels of C-reactive protein (CRP), procalcitonin and presepsin. Methods. This cross-sectional study included 479 adult patients hospitalized in the Clinical Center Kragujevac during 2019, who were suspected to have systemic infection and whose microbiological analyses were positive. Results. In a sample of hospital patients with isolated bacteria from the sites of suspected infection, the parameters of inflammation showed low agreement when used for diagnosing systemic infection. Only presepsin serum levels showed significant level of agreement with CRP and procalcitonin (Cohen's kappa = 0,257, p = 0,000Cohen's kappa = 0,169, p = 0,000, respectively, but also with low kappa values, while the agreement between CRP and procalcitonin was insignificant, as well as between the white cell count and the remaining three parameters. Conclusions. When disparate values of parameters of inflammation are encountered in a patient with suspected sepsis, a decision about antibiotic therapy should be based on either of the two pairs of parameters, presepsin/C-reactive protein or presepsin/procalcitonin.
References
1.
Feist B. Screening for sepsis: SIRS or qSOFA? A literature review. Emergency Nurse. 2019;27(6):13–8.
2.
Lu B, Zhang Y, Li C, Liu C, Yao Y, Su M, et al. The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis. The American Journal of Emergency Medicine. 2018;36(8):1341–5.
3.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2013;13(5):426–35.
4.
Yamamoto T, Nishimura T, Kaga S, Uchida K, Tachibana Y, Esaki M, et al. Diagnostic accuracy of presepsin for sepsis by the new Sepsis-3 definitions. The American Journal of Emergency Medicine. 2019;37(10):1936–41.
5.
Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Annals of Intensive Care. 2017;7(1).
6.
Chen KF, Chaou CH, Jiang JY, Yu HW, Meng YH, Tang WC, et al. Diagnostic Accuracy of Lipopolysaccharide-Binding Protein as Biomarker for Sepsis in Adult Patients: A Systematic Review and Meta-Analysis. PLOS ONE. 11(4):e0153188.
7.
Napolitano F, Giudice V, Selleri C, Montuori N. Plasminogen System in the Pathophysiology of Sepsis: Upcoming Biomarkers. International Journal of Molecular Sciences. 24(15):12376.
8.
Lu Y hua, Liu L, Qiu X hua, Yu Q, Yang Y, Qiu H bo. Effect of early goal directed therapy on tissue perfusion in patients with septic shock. World Journal of Emergency Medicine. 2013;4(2):117.
9.
Yurttutan Uyar N, Sayar AK, Kocagöz AS, Serdar MA, Zengin R, Sarıkaya ZT, et al. Sepsis biomarkers for early diagnosis of bacteremia in emergency department. The Journal of Infection in Developing Countries. 17(06):832–9.
10.
Zhu Y, Li X, Guo P, Chen Y, Li J, Tao T. <p>The accuracy assessment of presepsin (sCD14-ST) for mortality prediction in adult patients with sepsis and a head-to-head comparison to PCT: a meta-analysis</p> Therapeutics and Clinical Risk Management. Volume 15:741–53.
11.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine. 2017;45(3):486–552.
12.
Liu Y, Hou J huan, Li Q, Chen K jun, Wang SN, Wang J min. Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis. SpringerPlus. 2016;5(1).
13.
Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock – a systematic review and meta-analysis. Critical Care. 17(6).
14.
Yaegashi Y, Sato N, Suzuki Y, Kojika M, Imai S, Takahashi G, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. Journal of Infection and Chemotherapy. 2005;11(5):234–8.
15.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Endo S, Okamura Y. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. Journal of Infection and Chemotherapy. 2011;17(6):764–9.
16.
Schupp T, Weidner K, Rusnak J, Jawhar S, Forner J, Dulatahu F, et al. C-reactive protein and procalcitonin during course of sepsis and septic shock. Irish Journal of Medical Science (1971 -). 2024;193(1):457–68.
17.
Lazzarotto C, Ronsoni MF, Fayad L, Nogueira CL, Bazzo ML, Narciso-Schiavon JL, et al. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Annals of Hepatology. 2013;12(4):431–9.
18.
Fan SL, Miller NS, Lee J, Remick DG. Diagnosing sepsis – The role of laboratory medicine. Clinica Chimica Acta. 2016;460:203–10.
19.
Fleischmann-Struzek C, Rudd K. Challenges of assessing the burden of sepsis. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 2023;118(S2):68–74.
20.
Prest J, Nguyen T, Rajah T, Prest AB, Sathananthan M, Jeganathan N. Sepsis-Related Mortality Rates and Trends Based on Site of Infection. Critical Care Explorations. 4(10):e0775.
21.
Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395(10219):200–11.
22.
Hajj J, Blaine N, Salavaci J, Jacoby D. The “Centrality of Sepsis”: A Review on Incidence, Mortality, and Cost of Care. Healthcare. 6(3):90.
23.
Chakraborty RK, Burns B. Systemic inflammatory response syndrome [Internet.
24.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*. Critical Care Medicine. 2006;34(6):1589–96.
25.
Aiesh BM, Daraghmeh D, Abu-Shamleh N, Joudallah A, Sabateen A, Al Ramahi R. Blood culture contamination in a tertiary care hospital: a retrospective three-year study. BMC Infectious Diseases. 23(1).
26.
Megged O, Dorembus S, Ben‐Shalom E, Heiman E. Comparing blood culture contamination rates by different sampling methods in a paediatric emergency department. Journal of Paediatrics and Child Health. 2022;58(4):669–73.
27.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801.
28.
Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. C-reactive protein as a marker of infection in critically ill patients. Clinical Microbiology and Infection. 2005;11(2):101–8.
29.
Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY. Diagnosis and follow-up of infections in intensive care patients: Value of C-reactive protein compared with other clinical and biological variables*. Critical Care Medicine. 2002;30(3):529–35.
30.
Zhang Z, Ni H. C-Reactive Protein as a Predictor of Mortality in Critically Ill Patients: A Meta-Analysis and Systematic Review. Anaesthesia and Intensive Care. 2011;39(5):854–61.
31.
Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clinica Chimica Acta. 2011;412(23–24):2157–61.
32.
Mayo Foundation for Medical Education and Research.
33.
Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. The Lancet. 1993;341(8844):515–8.
34.
Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. The Journal of Maternal-Fetal & Neonatal Medicine. 2011;24(sup2):12–4.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
